Diabetic mesenchymal stem cells are ineffective for improving limb ischemia due to their impaired angiogenic capability

Cell Transplantation

Volumn 24, Issue 8, 2015, Pages 1571-1584

  Kim, Hyongbum ^a,b   Han, Ji Woong ^a   Lee, Ji Yoon ^a,c   Choi, Yong Jin ^a,d   Sohn, Young Doug ^a   Song, Myungjae ^b   Yoon, Young Sup ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hanyang University College of Medicine   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Diabetes mellitus; Ischemic; Mesenchymal stem cells (MSCs)

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PROTEIN AKT1; PROTEIN GAPDH; PROTEIN KINASE B; SCATTER FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; AKT1 PROTEIN, RAT;

ADHERENT CELL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DEVELOPMENT; CAPILLARY DENSITY; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIMB ISCHEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; THERAPY EFFECT; ANIMAL; BLOOD VESSEL; CAPILLARY; CYTOLOGY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; HINDLIMB; ISCHEMIA; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

RATTUS;

ANIMALS; BLOOD VESSELS; CAPILLARIES; CELL DIFFERENTIATION; CELL PROLIFERATION; COCULTURE TECHNIQUES; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HINDLIMB; HUMANS; ISCHEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-AKT; RATS;

EID: 84938876494     PISSN: 09636897     EISSN: 15553892     Source Type: Journal    
DOI: 10.3727/096368914X682792     Document Type: Article

References (61)

1. Ackah, E.; Yu, J.; Zoellner, S.; Iwakiri, Y.; Skurk, C.; Shibata, R.; Ouchi, N.; Easton, R. M.; Galasso, G.; Birnbaum, M. J.; Walsh, K.; Sessa, W. C. Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J. Clin. Invest. 115(8):2119–2127; 2005.
2. Al-Khaldi, A.; Eliopoulos, N.; Martineau, D.; Lejeune, L.; Lachapelle, K.; Galipeau, J. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther. 10(8):621–629; 2003.
3. Amado, L. C.; Saliaris, A. P.; Schuleri, K. H.; St John, M.; Xie, J. S.; Cattaneo, S.; Durand, D. J.; Fitton, T.; Kuang, J. Q.; Stewart, G.; Lehrke, S.; Baumgartner, W. W.; Martin, B. J.; Heldman, A. W.; Hare, J. M. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl. Acad. Sci. USA 102(32):11474–11479; 2005.
4. Baddoo, M.; Hill, K.; Wilkinson, R.; Gaupp, D.; Hughes, C.; Kopen, G. C.; Phinney, D. G. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J. Cell. Biochem. 89(6):1235–1249; 2003.
5. Brasacchio, D.; Okabe, J.; Tikellis, C.; Balcerczyk, A.; George, P.; Baker, E. K.; Calkin, A. C.; Brownlee, M.; Cooper, M. E.; El-Osta, A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58(5):1229– 1236; 2009.
6. Bronckaers, A.; Hilkens, P.; Martens, W.; Gervois, P.; Ratajczak, J.; Struys, T.; Lambrichts, I. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacol. Ther. 143(2):186–196; 2014.
7. Capla, J. M.; Grogan, R. H.; Callaghan, M. J.; Galiano, R. D.; Tepper, O. M.; Ceradini, D. J.; Gurtner, G. C. Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plast. Reconstr. Surg. 119(1):59–70; 2007.
8. Chang, W.; Song, B. W.; Lim, S.; Song, H.; Shim, C. Y.; Cha, M. J.; Ahn, D. H.; Jung, Y. G.; Lee, D. H.; Chung, J. H.; Choi, K. D.; Lee, S. K.; Chung, N.; Jang, Y.; Hwang, K. C. Mesenchymal stem cells pretreated with delivered Hph-1Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 27(9):2283–2292; 2009.
9. Cho, H. J.; Lee, N.; Lee, J. Y.; Choi, Y. J.; Ii, M.; Wecker, A.; Jeong, J. O.; Curry, C.; Qin, G.; Yoon, Y. S. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J. Exp. Med. 204(13):3257–3269; 2007.
10. Couffinhal, T.; Silver, M.; Zheng, L. P.; Kearney, M.; Witzenbichler, B.; Isner, J. M. Mouse model of angiogenesis. Am. J. Pathol. 152(6):1667–1679; 1998.
11. de Paula, F. J.; Horowitz, M. C.; Rosen, C. J. Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab. Res. Rev. 26(8):622–630; 2010.
12. Digirolamo, C. M.; Stokes, D.; Colter, D.; Phinney, D. G.; Class, R.; Prockop, D. J. Propagation and senescence of human marrow stromal cells in culture: A simple colonyforming assay identifies samples with the greatest potential to propagate and differentiate. Br. J. Haematol. 107(2):275– 281; 1999.
13. Efimenko, A.; Dzhoyashvili, N.; Kalinina, N.; Kochegura, T.; Akchurin, R.; Tkachuk, V.; Parfyonova, Y. Adiposederived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potential. Stem Cells Transl. Med. 3(1):32–41; 2014.
14. El-Osta, A.; Brasacchio, D.; Yao, D.; Pocai, A.; Jones, P. L.; Roeder, R. G.; Cooper, M. E.; Brownlee, M. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205(10):2409–2417; 2008.
15. Gnecchi, M.; He, H.; Liang, O. D.; Melo, L. G.; Morello, F.; Mu, H.; Noiseux, N.; Zhang, L.; Pratt, R. E.; Ingwall, J. S.; Dzau, V. J. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 11(4):367–368; 2005.
16. Gnecchi, M.; He, H.; Melo, L. G.; Noiseaux, N.; Morello, F.; de Boer, R. A.; Zhang, L.; Pratt, R. E.; Dzau, V. J.; Ingwall, J. S. Early beneficial effects of bone marrowderived mesenchymal stem cells overexpressing Akt on cardiac metabolism after myocardial infarction. Stem Cells 27(4):971–979; 2009.
17. Hossain, P.; Kawar, B.; El Nahas, M. Obesity and diabetes in the developing world--A growing challenge. N. Engl. J. Med. 356(3):213–215; 2007.
18. Ishikane, S.; Ohnishi, S.; Yamahara, K.; Sada, M.; Harada, K.; Mishima, K.; Iwasaki, K.; Fujiwara, M.; Kitamura, S.; Nagaya, N.; Ikeda, T. Allogeneic injection of fetal membrane-derived mesenchymal stem cells induces therapeutic angiogenesis in a rat model of hind limb ischemia. Stem Cells 26(10):2625–2633; 2008.
19. Ishizeki, K.; Saito, H.; Shinagawa, T.; Fujiwara, N.; Nawa, T. Histochemical and immunohistochemical analysis of the mechanism of calcification of Meckel’s cartilage during mandible development in rodents. J. Anat. 194 (Pt 2):265– 277; 1999.
20. Isidro, M. L.; Ruano, B. Bone disease in diabetes. Curr. Diabetes Rev. 6(3):144–155; 2010.
21. Jaiswal, N.; Haynesworth, S. E.; Caplan, A. I.; Bruder, S. P. Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J. Cell. Biochem. 64(2):295–312; 1997.
22. Jarajapu, Y. P.; Grant, M. B. The promise of cell-based therapies for diabetic complications: Challenges and solutions. Circ. Res. 106(5):854–869; 2010.
23. Kalka, C.; Masuda, H.; Takahashi, T.; Kalka-Moll, W. M.; Silver, M.; Kearney, M.; Li, T.; Isner, J. M.; Asahara, T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc. Natl. Acad. Sci. USA 97(7):3422–3427; 2000.
24. Karar, J.; Maity, A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 4:51; 2011.
25. Kim, H.; Cho, H. J.; Kim, S. W.; Liu, B.; Choi, Y. J.; Lee, J.; Sohn, Y. D.; Lee, M. Y.; Houge, M. A.; Yoon, Y. S. CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: Novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease. Circ. Res. 107(5):602–614; 2010.
26. Kim, H.; Park, J. S.; Choi, Y. J.; Kim, M. O.; Huh, Y. H.; Kim, S. W.; Han, J. W.; Lee, J.; Kim, S.; Houge, M. A.; Ii, M.; Yoon, Y. S. Bone marrow mononuclear cells have neurovascular tropism and improve diabetic neuropathy. Stem Cells 27(7):1686–1696; 2009.
27. Kim, H.; Suh, H.; Jo, S. A.; Kim, H. W.; Lee, J. M.; Kim, E. H.; Reinwald, Y.; Park, S. H.; Min, B. H.; Jo, I. In vivo bone formation by human marrow stromal cells in biodegradable scaffolds that release dexamethasone and ascorbate-2-phosphate. Biochem. Biophys. Res. Commun. 332(4):1053–1060; 2005.
28. Kim, S. W.; Han, H.; Chae, G. T.; Lee, S. H.; Bo, S.; Yoon, J. H.; Lee, Y. S.; Lee, K. S.; Park, H. K.; Kang, K. S. Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger’s disease and ischemic limb disease animal model. Stem Cells 24(6):1620–1626; 2006.
29. Kim, S. W.; Kim, H.; Cho, H. J.; Lee, J. U.; Levit, R.; Yoon, Y. S. Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease. J. Am. Coll. Cardiol. 56(7):593–607; 2010.
30. Kinnaird, T.; Stabile, E.; Burnett, M. S.; Epstein, S. E. Bone-marrow-derived cells for enhancing collateral development: Mechanisms, animal data, and initial clinical experiences. Circ. Res. 95(4):354–363; 2004.
31. Kinnaird, T.; Stabile, E.; Burnett, M. S.; Lee, C. W.; Barr, S.; Fuchs, S.; Epstein, S. E. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 94(5):678–685; 2004.
32. Kinnaird, T.; Stabile, E.; Burnett, M. S.; Shou, M.; Lee, C. W.; Barr, S.; Fuchs, S.; Epstein, S. E. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 109(12):1543– 1549; 2004.
33. Kolf, C. M.; Cho, E.; Tuan, R. S. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: Regulation of niche, self-renewal and differentiation. Arthritis Res. Ther. 9(1):204; 2007.
34. Lee, R. H.; Pulin, A. A.; Seo, M. J.; Kota, D. J.; Ylostalo, J.; Larson, B. L.; Semprun-Prieto, L.; Delafontaine, P.; Prockop, D. J. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 5(1):54–63; 2009.
35. Lennon, D. P.; Caplan, A. I. Isolation of rat marrow-derived mesenchymal stem cells. Exp. Hematol. 34(11):1606–1607; 2006.
36. Li, W. Y.; Choi, Y. J.; Lee, P. H.; Huh, K.; Kang, Y. M.; Kim, H. S.; Ahn, Y. H.; Lee, G.; Bang, O. Y. Mesenchymal stem cells for ischemic stroke: Changes in effects after ex vivo culturing. Cell Transplant. 17(9):1045–1059; 2008.
37. Loomans, C. J.; de Koning, E. J.; Staal, F. J.; Rookmaaker, M. B.; Verseyden, C.; de Boer, H. C.; Verhaar, M. C.; Braam, B.; Rabelink, T. J.; van Zonneveld, A. J. Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53(1):195–199; 2004.
38. Mangi, A. A.; Noiseux, N.; Kong, D.; He, H.; Rezvani, M.; Ingwall, J. S.; Dzau, V. J. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9(9):1195–1201; 2003.
39. McCabe, L. R. Understanding the pathology and mechanisms of type I diabetic bone loss. J. Cell. Biochem. 102(6):1343–1357; 2007.
40. Mias, C.; Lairez, O.; Trouche, E.; Roncalli, J.; Calise, D.; Seguelas, M. H.; Ordener, C.; Piercecchi-Marti, M. D.; Auge, N.; Salvayre, A. N.; Bourin, P.; Parini, A.; Cussac, D. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 27(11):2734–2743; 2009.
41. Murohara, T.; Asahara, T.; Silver, M.; Bauters, C.; Masuda, H.; Kalka, C.; Kearney, M.; Chen, D.; Symes, J. F.; Fishman, M. C.; Huang, P. L.; Isner, J. M. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J. Clin. Invest. 101(11):2567–2578; 1998.
42. Noiseux, N.; Gnecchi, M.; Lopez-Ilasaca, M.; Zhang, L.; Solomon, S. D.; Deb, A.; Dzau, V. J.; Pratt, R. E. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol. Ther. 14(6):840–850; 2006.
43. Ohgushi, H.; Dohi, Y.; Katuda, T.; Tamai, S.; Tabata, S.; Suwa, Y. In vitro bone formation by rat marrow cell culture. J. Biomed. Mater. Res. 32(3):333–340; 1996.
44. Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S.; Marshak, D. R. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411): 143–147; 1999.
45. Quevedo, H. C.; Hatzistergos, K. E.; Oskouei, B. N.; Feigenbaum, G. S.; Rodriguez, J. E.; Valdes, D.; Pattany, P. M.; Zambrano, J. P.; Hu, Q.; McNiece, I.; Heldman, A. W.; Hare, J. M. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl. Acad. Sci. USA 106(33):14022–14027; 2009.
46. Ramirez-Zacarias, J. L.; Castro-Munozledo, F.; Kuri Harcuch, W. Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with Oil red O. Histochemistry 97(6):493–497; 1992.
47. Sekiya, I.; Larson, B. L.; Vuoristo, J. T.; Cui, J. G.; Prockop, D. J. Adipogenic differentiation of human adult stem cells from bone marrow stroma (MSCs). J. Bone Miner. Res. 19(2):256–264; 2004.
48. Silva, G. V.; Litovsky, S.; Assad, J. A.; Sousa, A. L.; Martin, B. J.; Vela, D.; Coulter, S. C.; Lin, J.; Ober, J.; Vaughn, W. K.; Branco, R. V.; Oliveira, E. M.; He, R.; Geng, Y. J.; Willerson, J. T.; Perin, E. C. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation 111(2):150–156; 2005.
49. Stamler, J.; Vaccaro, O.; Neaton, J. D.; Wentworth, D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16(2):434–444; 1993.
50. Stolzing, A.; Sellers, D.; Llewelyn, O.; Scutt, A. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 191(6):453–465; 2010.
51. Takeshita, S.; Zheng, L. P.; Brogi, E.; Kearney, M.; Pu, L. Q.; Bunting, S.; Ferrara, N.; Symes, J. F.; Isner, J. M. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 93(2):662–670; 1994.
52. Tamarat, R.; Silvestre, J. S.; Le Ricousse-Roussanne, S.; Barateau, V.; Lecomte-Raclet, L.; Clergue, M.; Duriez, M.; Tobelem, G.; Levy, B. I. Impairment in ischemia-induced neovascularization in diabetes: Bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am. J. Pathol. 164(2):457–466; 2004.
53. Tepper, O. M.; Galiano, R. D.; Capla, J. M.; Kalka, C.; Gagne, P. J.; Jacobowitz, G. R.; Levine, J. P.; Gurtner, G. C. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22):2781–2786; 2002.
54. Thum, T.; Fraccarollo, D.; Schultheiss, M.; Froese, S.; Galuppo, P.; Widder, J. D.; Tsikas, D.; Ertl, G.; Bauersachs, J. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes 56(3):666–674; 2007.
55. Uccelli, A.; Moretta, L.; Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 8(9):726– 736; 2008.
56. Volarevic, V.; Arsenijevic, N.; Lukic, M. L.; Stojkovic, M. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells 29(1):5–10; 2011.
57. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053; 2004.
58. Williams, A. R.; Trachtenberg, B.; Velazquez, D. L.; McNiece, I.; Altman, P.; Rouy, D.; Mendizabal, A. M.; Pattany, P. M.; Lopera, G. A.; Fishman, J.; Zambrano, J. P.; Heldman, A. W.; Hare, J. M. Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: Functional recovery and reverse remodeling. Circ. Res. 108(7):792–796; 2011.
59. Wu, Y.; Chen, L.; Scott, P. G.; Tredget, E. E. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 25(10):2648–2659; 2007.
60. Yan, J.; Tie, G.; Wang, S.; Messina, K. E.; DiDato, S.; Guo, S.; Messina, L. M. Type 2 diabetes restricts multipotency of mesenchymal stem cells and impairs their capacity to augment postischemic neovascularization in db/db mice. J. Am. Heart Assoc. 1(6):e002238; 2012.
61. Yoon, Y. S.; Uchida, S.; Masuo, O.; Cejna, M.; Park, J. S.; Gwon, H. C.; Kirchmair, R.; Bahlman, F.; Walter, D.; Curry, C.; Hanley, A.; Isner, J. M.; Losordo, D. W. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: Restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111(16):2073–2085; 2005.